ArticleVirology2009
Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide.
Article in Virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- The Entry Blocker Peptide Produced inFrontiers in plant science · 2021Article
- Marine peptides and their anti-infective activities.Marine drugs · 2015Review
- Peptide entry inhibitors of enveloped viruses: the importance of interfacial hydrophobicity.Biochimica et biophysica acta · 2014Review
- Cathelicidin LL-37 and HSV-1 Corneal Infection: Peptide Versus Gene Therapy.Translational vision science & technology · 2014Article
- Antiviral activity of the EB peptide against zoonotic poxviruses.Virology journal · 2012Article
- Identification of the minimal active sequence of an anti-influenza virus peptide.Antimicrobial agents and chemotherapy · 2011Article
- Evaluation of therapeutic interventions for vaccinia virus keratitis.The Journal of infectious diseases · 2011Article
- Article
- A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2010Article
- The virucidal EB peptide protects host cells from herpes simplex virus type 1 infection in the presence of serum albumin and aggregates proteins in a detergent-like manner.Antimicrobial agents and chemotherapy · 2010Article
- A quantitative rabbit model of vaccinia keratitis.Investigative ophthalmology & visual science · 2010Article
- Kinetics of immune cell infiltration in vaccinia virus keratitis.Investigative ophthalmology & visual science · 2010Article
- Antiviral activity of selected antimicrobial peptides against vaccinia virus.Antiviral research · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Concerns about the possible use of Variola virus, the causative agent of smallpox, as a weapon for bioterrorism have led to renewed efforts to identify new antivirals against orthopoxviruses. We identified a peptide, EB, which inhibited infection by Vaccinia virus with an EC(50) of 15 microM. A control peptide, EBX, identical in composition to EB but differing in sequence, was inactive (EC50>200 microM), indicating sequence specificity. The inhibition was reversed upon removal of the peptide, and EB treatment had no effect on the physical integrity of virus particles as determined by electron microscopy. Viral adsorption was unaffected by the presence of EB, and the addition of EB post-entry had no effect on viral titers or on early gene expression. The addition of EB post-adsorption resulted in the inhibition of beta-galactosidase expression from an early viral promoter with an EC(50) of 45 microM. A significant reduction in virus entry was detected in the presence of the peptide when the number of viral cores released into the cytoplasm was quantified. Electron microscopy indicated that 88% of the virions remained on the surface of cells in the presence of EB, compared to 37% in the control (p<0.001). EB also blocked fusion-from-within, suggesting that virus infection is inhibited at the fusion step. Analysis of EB derivatives suggested that peptide length may be important for the activity of EB. The EB peptide is, to our knowledge, the first known small molecule inhibitor of Vaccinia virus entry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.